1. Volume 79, Issue 1, Pages 112-119 (January 2011)
Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism 
Katherine Wesseling-Perry, Renata C. Pereira, Shobha Sahney, Barbara Gales, He-Jing Wang, Robert Elashoff, Harald Jüppner, Isidro B. Salusky 
Kidney International 
Volume 79, Issue 1, Pages (January 2011)
DOI: /ki
Copyright © 2011 International Society of Nephrology Terms and Conditions

2. Figure 1
Serum calcium (S-Ca) levels throughout the course of the study by treatment group. Treatment groups: (1) 1αD2+CaCO3 (closed diamonds), (2) 1αD2+sevelamer (open diamonds), (3) calcitriol+CaCO3 (closed squares), and (4) calcitriol+sevelamer (open squares). Asterisk indicates P<0.01 from baseline and from sevelamer-treated patients. 1αD2, doxercalciferol; CaCO3, calcium carbonate.
Kidney International  , DOI: ( /ki )
Copyright © 2011 International Society of Nephrology Terms and Conditions

3. Figure 2
Serum phosphate (S-Phos) levels throughout the course of the study by treatment group. Treatment groups: (1) 1αD2+CaCO3 (closed diamonds), (2) 1αD2+sevelamer (open diamonds), (3) calcitriol+CaCO3 (closed squares), and (4) calcitriol+sevelamer (open squares). 1αD2, doxercalciferol; CaCO3, calcium carbonate.
Kidney International  , DOI: ( /ki )
Copyright © 2011 International Society of Nephrology Terms and Conditions

4. Figure 3
Plasma PTH levels throughout the course of treatment. (a) Plasma PTH levels throughout the course of the study by treatment group and (b) plasma PTH levels expressed as percent change from baseline among the four treatment groups. Treatment groups: (1) 1αD2+CaCO3 (closed diamonds), (2) 1αD2+sevelamer (open diamonds), (3) calcitriol+CaCO3 (closed squares), and (4) calcitriol+sevelamer (open squares). Asterisk indicates P<0.01 from baseline. 1αD2, doxercalciferol; 1st PTH-IMA, first-generation parathyroid hormone immunometric assay; CaCO3, calcium carbonate.
Kidney International  , DOI: ( /ki )
Copyright © 2011 International Society of Nephrology Terms and Conditions

5. Figure 4
Plasma FGF-23 levels throughout the course of treatment. (a) Plasma intact fibroblast growth factor-23 (FGF-23) levels throughout the course of the study by treatment group and (b) plasma C-terminal FGF-23 levels throughout the course of the study by treatment group. Treatment groups: (1) 1αD2+CaCO3 (closed diamonds), (2) 1αD2+sevelamer (open diamonds), (3) calcitriol+CaCO3 (closed squares), and (4) calcitriol+sevelamer (open squares). Asterisk indicates P<0.01 from baseline. 1αD2, doxercalciferol; CaCO3, calcium carbonate.
Kidney International  , DOI: ( /ki )
Copyright © 2011 International Society of Nephrology Terms and Conditions

6. Figure 5
Vitamin D sterol doses (expressed in calcitriol equivalents) throughout the course of the study by treatment group. Treatment groups: (1) 1αD2+CaCO3 (closed diamonds), (2) 1αD2+sevelamer (open diamonds), (3) calcitriol+CaCO3 (closed squares) and (4) calcitriol+sevelamer (open squares). 1αD2, doxercalciferol; CaCO3, calcium carbonate.
Kidney International  , DOI: ( /ki )
Copyright © 2011 International Society of Nephrology Terms and Conditions

7. Figure 6
Study protocol. CaCO3, calcium carbonate; PTH, parathyroid hormone.
Kidney International  , DOI: ( /ki )
Copyright © 2011 International Society of Nephrology Terms and Conditions